Leading synthetic biologists have shared hard-won lessons from their decade-long quest to build the world's first synthetic ...

Professors Guillermo Ameer and Cheng Sun contributed to work that points to a new approach for heart bypass grafts.

Musculoskeletal disorders and injuries are a leading cause of disability worldwide, severely affecting quality of life and creating a significant ...

As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...

Nanobiotix is a small French biotechnology company. It has secured financing from Johnson & Johnson and elsewhere. It's not a no-brainer investment, but it might do well. In its own words: "Nanobiotix ...

Connecticut’s biotech sector needs stronger digital-tech training, improved infrastructure and more robust state funding to sustain its growth, industry leaders said Wednesday. College students must ...

Bay Area startup ASC Therapeutics filed for bankruptcy on Wednesday, marking the end of the line for the gene and cell therapy researcher even as Health and Human Services Secretary Robert F. Kennedy ...

PEORIA — A new laboratory for a local biotech company received unanimous approval to move to a building in Central Peoria. Midwest Bioprocessing Center got a unanimous nod of approval from the Peoria ...

Students, industry leaders and government officials gathered at UCLA’s California NanoSystems Institute to learn about the future of biotechnology on Nov. 8. Biotech Connection Los Angeles – a ...

Shares of Korro Bio Inc. lost two-thirds of their value in the extended session Wednesday after the biotech company said it was pausing its work with Novo Nordisk, the weight loss-medication ...

Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO the inflammation biotech will use to fund a pair of clinical-stage candidates. The Palo Alto, California-based ...

Reader, beware: You’re entering haunted grounds. Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're embracing the spooky spirit of ...